Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 78 entries
Sorted by: Best Match Show Resources per page
Sebaceous-immunobiology is orchestrated by sebum lipids.

Dermato-endocrinology

Lovászi M, Szegedi A, Zouboulis CC, Törőcsik D.
PMID: 29484100
Dermatoendocrinol. 2017 Oct 17;9(1):e1375636. doi: 10.1080/19381980.2017.1375636. eCollection 2017.

The major role of sebaceous glands in mammals is to produce sebum, which coats the epidermis and the hair providing waterproofing, thermoregulation and photoprotection. However, as the need for these functions decreased along the evolutionary changes in humans, a...

Cite
Lovászi M, Szegedi A, Zouboulis CC, et al. Sebaceous-immunobiology is orchestrated by sebum lipids. Dermatoendocrinol. 2017;9(1):e1375636doi: 10.1080/19381980.2017.1375636.
Lovászi, M., Szegedi, A., Zouboulis, C. C., & Törőcsik, D. (2017). Sebaceous-immunobiology is orchestrated by sebum lipids. Dermato-endocrinology, 9(1), e1375636. https://doi.org/10.1080/19381980.2017.1375636
Lovászi, Marianna, et al. "Sebaceous-immunobiology is orchestrated by sebum lipids." Dermato-endocrinology vol. 9,1 (2017): e1375636. doi: https://doi.org/10.1080/19381980.2017.1375636
Lovászi M, Szegedi A, Zouboulis CC, Törőcsik D. Sebaceous-immunobiology is orchestrated by sebum lipids. Dermatoendocrinol. 2017 Oct 17;9(1):e1375636. doi: 10.1080/19381980.2017.1375636. eCollection 2017. PMID: 29484100; PMCID: PMC5821166.
Copy Download .nbib Format: NLM
Subjective Expectations Regarding Life Expectancy And Health-Related Quality Of Life In Moderate To Severe Psoriasis Patients.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research

Rencz F, Gulacsi L, Remenyik É, Szegedi A, Holló P, Kárpáti S, Péntek M, Brodszky V.
PMID: 27202132
Value Health. 2014 Nov;17(7):A611. doi: 10.1016/j.jval.2014.08.2142. Epub 2014 Oct 26.

No abstract available.

Cite
Rencz F, Gulacsi L, Remenyik É, et al. Subjective Expectations Regarding Life Expectancy And Health-Related Quality Of Life In Moderate To Severe Psoriasis Patients. Value Health. 2014;17(7):A611doi: 10.1016/j.jval.2014.08.2142.
Rencz, F., Gulacsi, L., Remenyik, �. �., Szegedi, A., Holló, P., Kárpáti, S., Péntek, M., & Brodszky, V. (2014). Subjective Expectations Regarding Life Expectancy And Health-Related Quality Of Life In Moderate To Severe Psoriasis Patients. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 17(7), A611. https://doi.org/10.1016/j.jval.2014.08.2142
Rencz, F, et al. "Subjective Expectations Regarding Life Expectancy And Health-Related Quality Of Life In Moderate To Severe Psoriasis Patients." Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research vol. 17,7 (2014): A611. doi: https://doi.org/10.1016/j.jval.2014.08.2142
Rencz F, Gulacsi L, Remenyik É, Szegedi A, Holló P, Kárpáti S, Péntek M, Brodszky V. Subjective Expectations Regarding Life Expectancy And Health-Related Quality Of Life In Moderate To Severe Psoriasis Patients. Value Health. 2014 Nov;17(7):A611. doi: 10.1016/j.jval.2014.08.2142. Epub 2014 Oct 26. PMID: 27202132.
Copy Download .nbib Format: NLM
Insoluble glycogen, a metabolizable internal adsorbent, decreases the lethality of endotoxin shock in rats.

Mediators of inflammation

Sipka S, Bot G, Gergely P, Bertók L, Csongor J, Sápy P, Szappanos M, Nemes J, Duda E, Szegedi G.
PMID: 18472865
Mediators Inflamm. 1997;6(5):319-22. doi: 10.1080/09629359791442.

Insoluble glycogen is an enzymatically modified form of naturally occurring soluble glycogen with a great adsorbing capacity. It can be metabolized by phagocytes to glucose. In this study we used insoluble glycogen intravenously in the experimental endotoxin shock of...

Cite
Sipka S, Bot G, Gergely P, et al. Insoluble glycogen, a metabolizable internal adsorbent, decreases the lethality of endotoxin shock in rats. Mediators Inflamm. 1997;6(5):319-22doi: 10.1080/09629359791442.
Sipka, S., Bot, G., Gergely, P., Bertók, L., Csongor, J., Sápy, P., Szappanos, M., Nemes, J., Duda, E., & Szegedi, G. (1997). Insoluble glycogen, a metabolizable internal adsorbent, decreases the lethality of endotoxin shock in rats. Mediators of inflammation, 6(5), 319-22. https://doi.org/10.1080/09629359791442
Sipka, S, et al. "Insoluble glycogen, a metabolizable internal adsorbent, decreases the lethality of endotoxin shock in rats." Mediators of inflammation vol. 6,5 (1997): 319-22. doi: https://doi.org/10.1080/09629359791442
Sipka S, Bot G, Gergely P, Bertók L, Csongor J, Sápy P, Szappanos M, Nemes J, Duda E, Szegedi G. Insoluble glycogen, a metabolizable internal adsorbent, decreases the lethality of endotoxin shock in rats. Mediators Inflamm. 1997;6(5):319-22. doi: 10.1080/09629359791442. PMID: 18472865; PMCID: PMC2365878.
Copy Download .nbib Format: NLM
Gene expression profiles of systemic lupus erythematosus and rheumatoid arthritis.

Expert review of clinical immunology

Centola M, Szekanecz Z, Kiss E, Zeher M, Szegedi G, Nakken B, Szodoray P.
PMID: 20477029
Expert Rev Clin Immunol. 2007 Sep;3(5):797-806. doi: 10.1586/1744666X.3.5.797.

Gene expression profiling using microarray technology is being employed to define specific molecular mediators and pathways involved in immunobiology, to understand the intricate interplay of genes participating in the pathogenesis, and to develop biomarkers of disease activity in both...

Cite
Centola M, Szekanecz Z, Kiss E, et al. Gene expression profiles of systemic lupus erythematosus and rheumatoid arthritis. Expert Rev Clin Immunol. 2007;3(5):797-806doi: 10.1586/1744666X.3.5.797.
Centola, M., Szekanecz, Z., Kiss, E., Zeher, M., Szegedi, G., Nakken, B., & Szodoray, P. (2007). Gene expression profiles of systemic lupus erythematosus and rheumatoid arthritis. Expert review of clinical immunology, 3(5), 797-806. https://doi.org/10.1586/1744666X.3.5.797
Centola, Michael, et al. "Gene expression profiles of systemic lupus erythematosus and rheumatoid arthritis." Expert review of clinical immunology vol. 3,5 (2007): 797-806. doi: https://doi.org/10.1586/1744666X.3.5.797
Centola M, Szekanecz Z, Kiss E, Zeher M, Szegedi G, Nakken B, Szodoray P. Gene expression profiles of systemic lupus erythematosus and rheumatoid arthritis. Expert Rev Clin Immunol. 2007 Sep;3(5):797-806. doi: 10.1586/1744666X.3.5.797. PMID: 20477029.
Copy Download .nbib Format: NLM
Association analysis between variants of the interleukin-1beta and the interleukin-1 receptor antagonist gene and antidepressant treatment response in major depression.

Neuropsychiatric disease and treatment

Tadić A, Rujescu D, Müller MJ, Kohnen R, Stassen HH, Szegedi A, Dahmen N.
PMID: 18728809
Neuropsychiatr Dis Treat. 2008 Feb;4(1):269-76. doi: 10.2147/ndt.s2262.

This study investigated the possible association of the interleukin-1 beta (IL-1beta) C-511T promoter polymorphism and the interleukin-1 receptor antagonist (IL-1Ra) (86bp)(n) variable number of tandem repeats (VNTR) polymorphism with antidepressant response to paroxetine and mirtazapine treatment. The study group...

Cite
Tadić A, Rujescu D, Müller MJ, et al. Association analysis between variants of the interleukin-1beta and the interleukin-1 receptor antagonist gene and antidepressant treatment response in major depression. Neuropsychiatr Dis Treat. 2008;4(1):269-76doi: 10.2147/ndt.s2262.
Tadić, A., Rujescu, D., Müller, M. J., Kohnen, R., Stassen, H. H., Szegedi, A., & Dahmen, N. (2008). Association analysis between variants of the interleukin-1beta and the interleukin-1 receptor antagonist gene and antidepressant treatment response in major depression. Neuropsychiatric disease and treatment, 4(1), 269-76. https://doi.org/10.2147/ndt.s2262
Tadić, André, et al. "Association analysis between variants of the interleukin-1beta and the interleukin-1 receptor antagonist gene and antidepressant treatment response in major depression." Neuropsychiatric disease and treatment vol. 4,1 (2008): 269-76. doi: https://doi.org/10.2147/ndt.s2262
Tadić A, Rujescu D, Müller MJ, Kohnen R, Stassen HH, Szegedi A, Dahmen N. Association analysis between variants of the interleukin-1beta and the interleukin-1 receptor antagonist gene and antidepressant treatment response in major depression. Neuropsychiatr Dis Treat. 2008 Feb;4(1):269-76. doi: 10.2147/ndt.s2262. PMID: 18728809; PMCID: PMC2515903.
Copy Download .nbib Format: NLM
Comparison of somnolence associated with asenapine, olanzapine, risperidone, and haloperidol relative to placebo in patients with schizophrenia or bipolar disorder.

Neuropsychiatric disease and treatment

Gao K, Mackle M, Cazorla P, Zhao J, Szegedi A.
PMID: 24003306
Neuropsychiatr Dis Treat. 2013;9:1145-57. doi: 10.2147/NDT.S41333. Epub 2013 Aug 22.

BACKGROUND: Patients with schizophrenia or bipolar disorder (BPD) may be differentially sensitive to antipsychotics. This study assessed the median time to onset, duration, and rate of somnolence associated with asenapine and other antipsychotics in both indications.METHODS: Ten clinical trials...

Cite
Gao K, Mackle M, Cazorla P, et al. Comparison of somnolence associated with asenapine, olanzapine, risperidone, and haloperidol relative to placebo in patients with schizophrenia or bipolar disorder. Neuropsychiatr Dis Treat. 2013;9:1145-57doi: 10.2147/NDT.S41333.
Gao, K., Mackle, M., Cazorla, P., Zhao, J., & Szegedi, A. (2013). Comparison of somnolence associated with asenapine, olanzapine, risperidone, and haloperidol relative to placebo in patients with schizophrenia or bipolar disorder. Neuropsychiatric disease and treatment, 91145-57. https://doi.org/10.2147/NDT.S41333
Gao, Keming, et al. "Comparison of somnolence associated with asenapine, olanzapine, risperidone, and haloperidol relative to placebo in patients with schizophrenia or bipolar disorder." Neuropsychiatric disease and treatment vol. 9 (2013): 1145-57. doi: https://doi.org/10.2147/NDT.S41333
Gao K, Mackle M, Cazorla P, Zhao J, Szegedi A. Comparison of somnolence associated with asenapine, olanzapine, risperidone, and haloperidol relative to placebo in patients with schizophrenia or bipolar disorder. Neuropsychiatr Dis Treat. 2013;9:1145-57. doi: 10.2147/NDT.S41333. Epub 2013 Aug 22. PMID: 24003306; PMCID: PMC3755703.
Copy Download .nbib Format: NLM
May Measurement Month 2017: an analysis of blood pressure screening in Hungary-Europe.

European heart journal supplements : journal of the European Society of Cardiology

Nemcsik J, Páll D, Ábrahám G, Barna I, Benczúr B, Fang S, Halmai R, Matoltsy A, Szegedi J, Várbíró S, Beaney T, Xia X, Poulter NR, Kiss I, Járai Z.
PMID: 31043879
Eur Heart J Suppl. 2019 Apr;21:D56-D58. doi: 10.1093/eurheartj/suz054. Epub 2019 Apr 24.

Elevated blood pressure (BP) is a growing burden worldwide, leading to over 10 million deaths each year. The cardiovascular mortality rate in Hungary is twice as high as the European Union average. In a recent Hungarian screening programme, among...

Cite
Nemcsik J, Páll D, Ábrahám G, et al. May Measurement Month 2017: an analysis of blood pressure screening in Hungary-Europe. Eur Heart J Suppl. 2019;21:D56-D58doi: 10.1093/eurheartj/suz054.
Nemcsik, J., Páll, D., Ábrahám, G., Barna, I., Benczúr, B., Fang, S., Halmai, R., Matoltsy, A., Szegedi, J., Várbíró, S., Beaney, T., Xia, X., Poulter, N. R., Kiss, I., & Járai, Z. (2019). May Measurement Month 2017: an analysis of blood pressure screening in Hungary-Europe. European heart journal supplements : journal of the European Society of Cardiology, 21D56-D58. https://doi.org/10.1093/eurheartj/suz054
Nemcsik, János, et al. "May Measurement Month 2017: an analysis of blood pressure screening in Hungary-Europe." European heart journal supplements : journal of the European Society of Cardiology vol. 21 (2019): D56-D58. doi: https://doi.org/10.1093/eurheartj/suz054
Nemcsik J, Páll D, Ábrahám G, Barna I, Benczúr B, Fang S, Halmai R, Matoltsy A, Szegedi J, Várbíró S, Beaney T, Xia X, Poulter NR, Kiss I, Járai Z. May Measurement Month 2017: an analysis of blood pressure screening in Hungary-Europe. Eur Heart J Suppl. 2019 Apr;21:D56-D58. doi: 10.1093/eurheartj/suz054. Epub 2019 Apr 24. PMID: 31043879; PMCID: PMC6479421.
Copy Download .nbib Format: NLM
Efficacy of ubrogepant based on prior exposure and response to triptans: A post hoc analysis.

Headache

Blumenfeld AM, Goadsby PJ, Dodick DW, Hutchinson S, Liu C, Finnegan M, Trugman JM, Szegedi A.
PMID: 33749826
Headache. 2021 Mar;61(3):422-429. doi: 10.1111/head.14089. Epub 2021 Mar 22.

OBJECTIVE: To determine the potential efficacy of ubrogepant for acute treatment of migraine based on historical experience with triptans.BACKGROUND: Although triptans have improved migraine treatment, their efficacy and tolerability may limit their utility in some individuals. Ubrogepant is a...

Cite
Blumenfeld AM, Goadsby PJ, Dodick DW, et al. Efficacy of ubrogepant based on prior exposure and response to triptans: A post hoc analysis. Headache. 2021;61(3):422-429doi: 10.1111/head.14089.
Blumenfeld, A. M., Goadsby, P. J., Dodick, D. W., Hutchinson, S., Liu, C., Finnegan, M., Trugman, J. M., & Szegedi, A. (2021). Efficacy of ubrogepant based on prior exposure and response to triptans: A post hoc analysis. Headache, 61(3), 422-429. https://doi.org/10.1111/head.14089
Blumenfeld, Andrew M, et al. "Efficacy of ubrogepant based on prior exposure and response to triptans: A post hoc analysis." Headache vol. 61,3 (2021): 422-429. doi: https://doi.org/10.1111/head.14089
Blumenfeld AM, Goadsby PJ, Dodick DW, Hutchinson S, Liu C, Finnegan M, Trugman JM, Szegedi A. Efficacy of ubrogepant based on prior exposure and response to triptans: A post hoc analysis. Headache. 2021 Mar;61(3):422-429. doi: 10.1111/head.14089. Epub 2021 Mar 22. PMID: 33749826; PMCID: PMC8252782.
Copy Download .nbib Format: NLM
Primary alterations during the development of hidradenitis suppurativa.

Journal of the European Academy of Dermatology and Venereology : JEADV

Dajnoki Z, Somogyi O, Medgyesi B, Jenei A, Szabó L, Gáspár K, Hendrik Z, Gergely P, Imre D, Póliska S, Törőcsik D, Zouboulis CC, Prens EP, Kapitány A, Szegedi A.
PMID: 34724272
J Eur Acad Dermatol Venereol. 2021 Nov 01; doi: 10.1111/jdv.17779. Epub 2021 Nov 01.

BACKGROUND: Hidradenitis suppurativa (HS) is a chronic, inflammatory disease of the apocrine gland-rich (AGR) skin region. The initial steps of disease development are not fully understood, despite intense investigations into immune alterations in lesional HS skin.OBJECTIVES: We aimed to...

Cite
Dajnoki Z, Somogyi O, Medgyesi B, et al. Primary alterations during the development of hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2021;doi: 10.1111/jdv.17779.
Dajnoki, Z., Somogyi, O., Medgyesi, B., Jenei, A., Szabó, L., Gáspár, K., Hendrik, Z., Gergely, P., Imre, D., Póliska, S., Törőcsik, D., Zouboulis, C. C., Prens, E. P., Kapitány, A., & Szegedi, A. (2021). Primary alterations during the development of hidradenitis suppurativa. Journal of the European Academy of Dermatology and Venereology : JEADV, . https://doi.org/10.1111/jdv.17779
Dajnoki, Z, et al. "Primary alterations during the development of hidradenitis suppurativa." Journal of the European Academy of Dermatology and Venereology : JEADV vol. (2021). doi: https://doi.org/10.1111/jdv.17779
Dajnoki Z, Somogyi O, Medgyesi B, Jenei A, Szabó L, Gáspár K, Hendrik Z, Gergely P, Imre D, Póliska S, Törőcsik D, Zouboulis CC, Prens EP, Kapitány A, Szegedi A. Primary alterations during the development of hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2021 Nov 01; doi: 10.1111/jdv.17779. Epub 2021 Nov 01. PMID: 34724272.
Copy Download .nbib Format: NLM
Hydrodemethoxylation/Dealkylation on Bifunctional Nanosized Zeolite Beta.

Molecules (Basel, Switzerland)

Popova M, Szegedi Á, Oykova M, Lazarova H, Koseva N, Mihályi MR, Karashanova D, Mitrev Y, Shestakova P.
PMID: 34946777
Molecules. 2021 Dec 20;26(24). doi: 10.3390/molecules26247694.

Mono-, and bimetallic Ni-, Ru-, and Pt-modified nanosized Beta zeolite catalysts were prepared by the post synthesis method and characterized by powder X-ray diffraction (XRD), nitrogen physisorption, HRTEM microscopy, temperature-programmed reduction (TPR-TGA), ATR FT-IR spectroscopy, and by solid-state MAS-NMR...

Cite
Popova M, Szegedi Á, Oykova M, et al. Hydrodemethoxylation/Dealkylation on Bifunctional Nanosized Zeolite Beta. Molecules. 2021;26(24)doi: 10.3390/molecules26247694.
Popova, M., Szegedi, �. �., Oykova, M., Lazarova, H., Koseva, N., Mihályi, M. R., Karashanova, D., Mitrev, Y., & Shestakova, P. (2021). Hydrodemethoxylation/Dealkylation on Bifunctional Nanosized Zeolite Beta. Molecules (Basel, Switzerland), 26(24), . https://doi.org/10.3390/molecules26247694
Popova, Margarita, et al. "Hydrodemethoxylation/Dealkylation on Bifunctional Nanosized Zeolite Beta." Molecules (Basel, Switzerland) vol. 26,24 (2021). doi: https://doi.org/10.3390/molecules26247694
Popova M, Szegedi Á, Oykova M, Lazarova H, Koseva N, Mihályi MR, Karashanova D, Mitrev Y, Shestakova P. Hydrodemethoxylation/Dealkylation on Bifunctional Nanosized Zeolite Beta. Molecules. 2021 Dec 20;26(24). doi: 10.3390/molecules26247694. PMID: 34946777; PMCID: PMC8708772.
Copy Download .nbib Format: NLM
Leptin Receptor (rs1137101) and Brain-Derived Neurotrophic Factor (rs925946) Gene Variants Are Associated with Obesity in the Early- but Not in the Late-Onset Population of Hungarian Psoriatic Patients.

Life (Basel, Switzerland)

Szentkereszty-Kovács Z, Fiatal S, Janka EA, Kovács D, Szegedi A, Remenyik É, Törőcsik D.
PMID: 34685457
Life (Basel). 2021 Oct 14;11(10). doi: 10.3390/life11101086.

BACKGROUND: Psoriatic patients have considerably higher odds of being obese compared with the general population; however, the exact pathophysiological link between psoriasis and obesity needs to be elucidated.METHODS: To investigate the association of psoriasis with established obesity-related gene variants,...

Cite
Szentkereszty-Kovács Z, Fiatal S, Janka EA, et al. Leptin Receptor (rs1137101) and Brain-Derived Neurotrophic Factor (rs925946) Gene Variants Are Associated with Obesity in the Early- but Not in the Late-Onset Population of Hungarian Psoriatic Patients. Life (Basel). 2021;11(10)doi: 10.3390/life11101086.
Szentkereszty-Kovács, Z., Fiatal, S., Janka, E. A., Kovács, D., Szegedi, A., Remenyik, �. �., & Törőcsik, D. (2021). Leptin Receptor (rs1137101) and Brain-Derived Neurotrophic Factor (rs925946) Gene Variants Are Associated with Obesity in the Early- but Not in the Late-Onset Population of Hungarian Psoriatic Patients. Life (Basel, Switzerland), 11(10), . https://doi.org/10.3390/life11101086
Szentkereszty-Kovács, Zita, et al. "Leptin Receptor (rs1137101) and Brain-Derived Neurotrophic Factor (rs925946) Gene Variants Are Associated with Obesity in the Early- but Not in the Late-Onset Population of Hungarian Psoriatic Patients." Life (Basel, Switzerland) vol. 11,10 (2021). doi: https://doi.org/10.3390/life11101086
Szentkereszty-Kovács Z, Fiatal S, Janka EA, Kovács D, Szegedi A, Remenyik É, Törőcsik D. Leptin Receptor (rs1137101) and Brain-Derived Neurotrophic Factor (rs925946) Gene Variants Are Associated with Obesity in the Early- but Not in the Late-Onset Population of Hungarian Psoriatic Patients. Life (Basel). 2021 Oct 14;11(10). doi: 10.3390/life11101086. PMID: 34685457; PMCID: PMC8538564.
Copy Download .nbib Format: NLM
Recent Advances in the Management of Pediatric Acute Myeloid Leukemia-Report of the Hungarian Pediatric Oncology-Hematology Group.

Cancers

Gaál Z, Jakab Z, Kárai B, Ujfalusi A, Petrás M, Kállay K, Kelemen Á, Simon R, Kriván G, Kovács GT, Kiss C, Szegedi I.
PMID: 34680225
Cancers (Basel). 2021 Oct 11;13(20). doi: 10.3390/cancers13205078.

Outcome measures of pediatric acute myeloid leukemia (AML) improved considerably between 1990 and 2011 in Hungary. Since 2012, efforts of the Hungarian Pediatric Oncology-Hematology Group (HPOG) included the reduction in the number of treatment centers, contemporary diagnostic procedures, vigorous...

Cite
Gaál Z, Jakab Z, Kárai B, et al. Recent Advances in the Management of Pediatric Acute Myeloid Leukemia-Report of the Hungarian Pediatric Oncology-Hematology Group. Cancers (Basel). 2021;13(20)doi: 10.3390/cancers13205078.
Gaál, Z., Jakab, Z., Kárai, B., Ujfalusi, A., Petrás, M., Kállay, K., Kelemen, �. �., Simon, R., Kriván, G., Kovács, G. T., Kiss, C., & Szegedi, I. (2021). Recent Advances in the Management of Pediatric Acute Myeloid Leukemia-Report of the Hungarian Pediatric Oncology-Hematology Group. Cancers, 13(20), . https://doi.org/10.3390/cancers13205078
Gaál, Zsuzsanna, et al. "Recent Advances in the Management of Pediatric Acute Myeloid Leukemia-Report of the Hungarian Pediatric Oncology-Hematology Group." Cancers vol. 13,20 (2021). doi: https://doi.org/10.3390/cancers13205078
Gaál Z, Jakab Z, Kárai B, Ujfalusi A, Petrás M, Kállay K, Kelemen Á, Simon R, Kriván G, Kovács GT, Kiss C, Szegedi I. Recent Advances in the Management of Pediatric Acute Myeloid Leukemia-Report of the Hungarian Pediatric Oncology-Hematology Group. Cancers (Basel). 2021 Oct 11;13(20). doi: 10.3390/cancers13205078. PMID: 34680225; PMCID: PMC8534106.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 78 entries